Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer

Cancer and Metastasis Reviews

Volumn 31, Issue 1-2, 2012, Pages 143-162

  Masoumi Moghaddam, Samar ^a   Amini, Afshin ^a   Morris, David L ^a   Pourgholami, Mohammad H ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Angiogenesis; Bevacizumab; Malignant ascites; Ovarian cancer; Peritoneal carcinomatosis; Vascular endothelial growth factor

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFLIBERCEPT; BEVACIZUMAB; CARBOPLATIN; CEDIRANIB; CISPLATIN; ENDOTHELIN 1; MOTESANIB; NINTEDANIB; PACLITAXEL; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; PLATINUM; RAMUCIRUMAB; SEMAXANIB; SORAFENIB; SUNITINIB; TUMOR NECROSIS FACTOR ALPHA; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VATALANIB;

ADVANCED CANCER; ANGIOGENESIS; ARTERY THROMBOSIS; BLEEDING; BLOOD VESSEL PERMEABILITY; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL EVALUATION; COLORECTAL CANCER; DISEASE COURSE; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HYPERTENSION; INTESTINE PERFORATION; LEUKOCYTE MIGRATION; LIVER METASTASIS; LUNG METASTASIS; MALIGNANT ASCITES; NONHUMAN; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA METASTASIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ASCITES; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862307591     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-011-9337-5     Document Type: Review

References (258)

1. Chung, A. S., & Ferrara, N. (2010). Developmental and pathological angiogenesis. Annual Review of Cell and Developmental Biology. doi:10.1146/annurev-cellbio-092910-154002.
2. Geva, E., & Jaffe, R. B. (2000). Role of vascular endothelial growth factor in ovarian physiology and pathology. Fertility and Sterility, 74(3), 429-438.
3. Ferlay, J., Shin, H. R., Bray, F., Forman, D., Mathers, C., &Parkin, D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International Journal of Cancer, 127(12), 2893-2917. doi:10.1002/ijc.25516.
4. Ramakrishnan, S., Subramanian, I. V., Yokoyama, Y., & Geller, M. (2005). Angiogenesis in normal and neoplastic ovaries. Angiogenesis, 8(2), 169-182. doi:10.1007/s10456-005-9001-1. (Pubitemid 41712846)
5. Nakanishi, Y., Kodama, J., Yoshinouchi, M., Tokumo, K., Kamimura, S., Okuda, H., et al. (1997). The expression of vascular endothelial growth factor and transforming growth factor-beta associates with angiogenesis in epithelial ovarian cancer. International Journal of Gynecological Pathology, 16(3), 256-262. (Pubitemid 27282300)
6. Mu, J., Abe, Y., Tsutsui, T., Yamamoto, N., Tai, X.-G., Niwa, O., et al. (1996). Inhibition of growth andmetastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Cancer Science, 87(9), 963-971. (Pubitemid 26328923)
7. Yamamoto, S., Konishi, I., Mandai, M., Kuroda, H., Komatsu, T., Nanbu, K., et al. (1997). Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. British Journal of Cancer, 76(9), 1221-1227. (Pubitemid 27448021)
8. Hartenbach, E. M., Olson, T. A., Goswitz, J. J., Mohanraj, D., Twiggs, L. B., Carson, L. F., et al. (1997). Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Letters, 121(2), 169-175. (Pubitemid 28008916)
9. Pannu, H. K., Bristow, R. E., Montz, F. J., & Fishman, E. K. (2003). Multidetector CT of peritoneal carcinomatosis from ovarian cancer1. RadioGraphics, 23(3), 687-701. doi:10.1148/rg.233025105. (Pubitemid 37431249)
10. Munoz-Casares, F. C., Rufian, S., Arjona-Sanchez, A., Rubio, M. J., Diaz, R., Casado, A., et al. (2011). Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study. Cancer Chemotherapy and Pharmacology, 68(1), 267-274. doi:10.1007/s00280-011-1646-4.
11. Meunier, L., Puiffe, M. L., Le Page, C., Filali-Mouhim, A., Chevrette, M., Tonin, P. N., et al. (2010). Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model. Transl Oncol, 3(4), 230-238.
12. Roszkowski, P., Wronkowski, Z., Szamborski, J., & Romejko, M. (1993). Evaluation of selected prognostic factors in ovarian cancer. European Journal of Gynaecological Oncology, 14 (Suppl), 140-145. (Pubitemid 24052688)
13. Zang, R. Y., Harter, P., Chi, D. S., Sehouli, J., Jiang, R., Trope, C. G., et al. (2011). Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. British Journal of Cancer, 105(7), 890-896.
14. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., & Dvorak, H. F. (1983). Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science, 219(4587), 983-985.
15. Ferrara, N., & Henzel,W. J. (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochemical and Biophysical Research Communications, 161(2), 851-858.
16. Connolly, D. T., Olander, J. V., Heuvelman, D., Nelson, R., Monsell, R., Siegel, N., et al. (1989). Human vascular permeability factor. Isolation from U937 cells. Journal of Biological Chemistry, 26(33), 20017-20024.
17. Keck, P. J., Hauser, S. D., Krivi, G., Sanzo, K., Warren, T., Feder, J., et al. (1989). Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science, 246(4935), 1309-1312. (Pubitemid 20066717)
18. Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V., &Ferrara, N. (1989). Vascular endothelial growth factor is a secreted angiogenic mitogen. Science, 246(4935), 1306-1309. (Pubitemid 20066716)
19. Yamazaki, Y., & Morita, T. (2006). Molecular and functional diversity of vascular endothelial growth factors. Molecular Diversity, 10(4), 515-527. doi:10.1007/s11030-006-9027-3. (Pubitemid 44885229)
20. Woolard, J., Bevan, H. S., Harper, S. J., & Bates, D. O. (2009). Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation, 16(7), 572-592. doi:10.1080/10739680902997333.
21. Kowanetz, M., & Ferrara, N. (2006). Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clinical Cancer Research, 12(17), 5018-5022. doi:10.1158/1078-0432.ccr-06-1520. (Pubitemid 44453326)
22. Crawford, Y., & Ferrara, N. (2009). VEGF inhibition: insights from preclinical and clinical studies. Cell and Tissue Research, 335(1), 261-269. doi:10.1007/s00441-008-0675-8.
23. Ferrara, N. (2010). Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Molecular Biology of the Cell, 21(5), 687-690. doi:10.1091/mbc.E09-07- 0590.
24. Olsson, A. K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006). VEGF receptor signalling - in control of vascular function. Nature Reviews Molecular Cell Biology, 7(5), 359-371. doi:10.1038/nrm1911.
25. Robinson, C. J., & Stringer, S. E. (2001). The splice variants of vascular endothelial growth factor (VEGF) and their receptors. Journal of Cell Science, 114(Pt 5), 853-865. (Pubitemid 32273121)
26. Jakeman, L. B.,Winer, J., Bennett, G. L., Altar, C. A., & Ferrara, N. (1992). Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. The Journal of Clinical Investigation, 89(1), 244-253. doi:10.1172/jci115568.
27. Jakeman, L. B., Armanini, M., Phillips, H. S., & Ferrara, N. (1993). Developmental expression of binding sites and messenger ribonucleic acid for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology, 133(2), 848-859. (Pubitemid 23238902)
28. Shen, H., Clauss, M., Ryan, J., Schmidt, A. M., Tijburg, P., Borden, L., et al. (1993). Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood, 81(10), 2767-2773. (Pubitemid 23147585)
29. Cross, M. J., Dixelius, J., Matsumoto, T., & Claesson-Welsh, L. (2003). VEGF-receptor signal transduction. Trends in Biochemical Sciences, 28(9), 488-494. (Pubitemid 38340413)
30. Ferrara, N., Gerber, H. P., & LeCouter, J. (2003). The biology of VEGF and its receptors. Nature Medicine, 9(6), 669-676. doi:10.1038/nm0603-669. (Pubitemid 36749215)
31. Makinen, T., Veikkola, T., Mustjoki, S., Karpanen, T., Catimel, B., Nice, E. C., et al. (2001). Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGFC/D receptor VEGFR-3. EMBO Journal, 20(17), 4762-4773. doi:10.1093/emboj/20.17.4762. (Pubitemid 32848629)
32. Gerber, H. P., McMurtrey, A., Kowalski, J., Yan, M., Keyt, B. A., Dixit, V., et al. (1998). Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. Journal of Biological Chemistry, 273(46), 30336-30343. (Pubitemid 28545503)
33. Gerber, H. P., Dixit, V., & Ferrara, N. (1998). Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. Journal of Biological Chemistry, 273(21), 13313-13316. (Pubitemid 28246905)
34. Tran, J., Rak, J., Sheehan, C., Saibil, S. D., LaCasse, E., Korneluk, R. G., et al. (1999). Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochemical and Biophysical Research Communications, 264(3), 781-788. doi:10.1006/bbrc.1999. 1589.
35. Chung, A. S., Lee, J., & Ferrara, N. (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. Nature Reviews. Cancer, 10(7), 505-514. doi:10.1038/nrc2868.
36. Bates, D. O., & Harper, S. J. (2002). Regulation of vascular permeability by vascular endothelial growth factors. Vascular Pharmacology, 39(4-5), 225-237. (Pubitemid 37490748)
37. Issbrucker, K., Marti, H. H., Hippenstiel, S., Springmann, G., Voswinckel, R., Gaumann, A., et al. (2003). p38 MAP kinase - a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. The FASEB Journal, 17(2), 262-264. doi:10.1096/fj.02-0329fje.
38. Kroll, J., & Waltenberger, J. (1999). A novel function of VEGF receptor-2 (KDR): rapid release of nitric oxide in response to VEGF-A stimulation in endothelial cells. Biochemical and Biophysical Research Communications, 265(3), 636-639. doi:10.1006/bbrc.1999.1729.
39. Yla-Herttuala, S., Rissanen, T. T., Vajanto, I., & Hartikainen, J. (2007). Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. Journal of the American College of Cardiology, 49(10), 1015-1026. doi:10.1016/j.jacc.2006.09.053. (Pubitemid 46349500)
40. Ferrara, N. (2001). Role of vascular endothelial growth factor in regulation of physiological angiogenesis. American Journal of Physiology. Cell Physiology, 280(6), C1358-C1366.
41. Brown, L. F., Yeo, K. T., Berse, B., Yeo, T. K., Senger, D. R., Dvorak, H. F., et al. (1992). Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. The Journal of Experimental Medicine, 176(5), 1375-1379.
42. Kumar, I., Staton, C. A., Cross, S. S., Reed, M. W., & Brown, N. J. (2009). Angiogenesis, vascular endothelial growth factor and its receptors in human surgical wounds. British Journal of Surgery, 96(12), 1484-1491. doi:10.1002/bjs.6778.
43. Westenbrink, B. D., Ruifrok, W. P., Voors, A. A., Tilton, R. G., van Veldhuisen, D. J., Schoemaker, R. G., et al. (2010). Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure. Cardiovascular Research, 87(1), 30-39. doi:10.1093/cvr/cvq041.
44. Lee, C., & Agoston, D. V. (2010). Vascular endothelial growth factor is involved in mediating increased de novo hippocampal neurogenesis in response to traumatic brain injury. Journal of Neurotrauma, 27(3), 541-553. doi:10.1089/neu.2009.0905.
45. Olfert, I. M., Howlett, R. A.,Wagner, P. D., & Breen, E. C. (2010). Myocyte vascular endothelial growth factor is required for exercise-induced skeletal muscle angiogenesis. American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, 299(4), R1059-R1067. doi:10.1152/ajpregu.00347.2010.
46. Taylor, P. D., Wilson, H., Hillier, S. G., Wiegand, S. J., & Fraser, H. M. (2007). Effects of inhibition of vascular endothelial growth factor at time of selection on follicular angiogenesis, expansion, development and atresia in the marmoset. Molecular Human Reproduction, 13(10), 729-736. doi:10.1093/molehr/gam056. (Pubitemid 47543411)
47. Kumaran, G. C., Jayson, G. C., & Clamp, A. R. (2009). Antiangiogenic drugs in ovarian cancer. British Journal of Cancer, 100(1), 1-7. doi:10.1038/sj.bjc.6604767.
48. Zimmermann, R. C., Xiao, E., Husami, N., Sauer, M. V., Lobo, R., Kitajewski, J., et al. (2001). Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. Journal of Clinical Endocrinology and Metabolism, 86 (2), 768-772.
49. Wulff, C., Wiegand, S. J., Saunders, P. T., Scobie, G. A., &Fraser, H. M. (2001). Angiogenesis during follicular development in the primate and its inhibition by treatment with truncated Flt-1-Fc (vascular endothelial growth factor Trap(A40)). Endocrinology, 142(7), 3244-3254. (Pubitemid 32575563)
50. Zimmermann, R. C., Xiao, E., Bohlen, P., & Ferin, M. (2002). Administration of antivascular endothelial growth factor receptor 2 antibody in the early follicular phase delays follicular selection and development in the rhesus monkey. Endocrinology, 143(7), 2496-2502. (Pubitemid 34701311)
51. Zimmermann, R. C.,Hartman, T., Kavic, S., Pauli, S. A., Bohlen, P., Sauer, M. V., et al. (2003). Vascular endothelial growth factor receptor 2-mediated angiogenesis is essential for gonadotropin-dependent follicle development. The Journal of Clinical Investigation, 112(5), 659-669. doi:10.1172/jci18740. (Pubitemid 38057707)
52. Fraser, H. M., Wilson, H., Rudge, J. S., & Wiegand, S. J. (2005). Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function. Journal of Clinical Endocrinology and Metabolism, 90(2), 1114-1122. doi:10.1210/jc.2004-1572. (Pubitemid 40279242)
53. Koos, R. D. (1995). Increased expression of vascular endothelial growth/permeability factor in the rat ovary following an ovulatory gonadotropin stimulus: potential roles in follicle rupture. Biology of Reproduction, 52(6), 1426-1435.
54. Ferrara, N., Chen, H., Davis-Smyth, T., Gerber, H. P., Nguyen, T. N., Peers, D., et al. (1998). Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nature Medicine, 4(3), 336-340. (Pubitemid 28144094)
55. Fraser, H. M., & Wulff, C. (2003). Angiogenesis in the corpus luteum. Reproductive Biology and Endocrinology, 1, 88. doi:10.1186/1477-7827-1-88.
56. Doyle, L. K., Walker, C. A., & Donadeu, F. X. (2010). VEGF modulates the effects of gonadotropins in granulosa cells. Domestic Animal Endocrinology, 38(3), 127-137. doi:10.1016/j.domaniend.2009.08.008.
57. Greenaway, J., Connor, K., Pedersen, H. G., Coomber, B. L., LaMarre, J., & Petrik, J. (2004). Vascular endothelial growth factor and its receptor, Flk-1/KDR, are cytoprotective in the extravascular compartment of the ovarian follicle. Endocrinology, 145(6), 2896-2905. doi:10.1210/en.2003-1620. (Pubitemid 38686239)
58. Grasselli, F., Basini, G., Bussolati, S., & Tamanini, C. (2002). Effects of VEGF and bFGF on proliferation and production of steroids and nitric oxide in porcine granulosa cells. Reproduction in Domestic Animals, 37(6), 362-368. doi:10.1046/j.1439-0531.2002.00386.x. (Pubitemid 36087383)
59. Rolaki, A., Coukos, G., Loutradis, D., DeLisser, H. M., Coutifaris, C., & Makrigiannakis, A. (2007). Luteogenic hormones act through a vascular endothelial growth factor-dependent mechanism to up-regulate α5β1 and αvβ3 integrins, promoting the migration and survival of human luteinized granulosa cells. American Journal of Pathology, 170(5), 1561-1572. doi:10.2353/ajpath.2007.060926. (Pubitemid 47339301)
60. Scott, A., Powner, M. B., Gandhi, P., Clarkin, C., Gutmann, D. H., Johnson, R. S., et al. (2010). Astrocyte-derived vascular endothelial growth factor stabilizes vessels in the developing retinal vasculature. PloS One, 5(7), e11863. doi:10.1371/journal.pone.0011863.
61. Smith, L. E. (2008). Through the eyes of a child: understanding retinopathy through ROP the Friedenwald lecture. Investigative Ophthalmology & Visual Science, 49(12), 5177-5182. doi:10.1167/iovs.08-2584.
62. Mahdy, R. A., Nada, W. M., Hadhoud, K. M., & El-Tarhony, S. A. (2010). The role of vascular endothelial growth factor in the progression of diabetic vascular complications. Eye (London, England), 24(10), 1576-1584. doi:10.1038/eye.2010.86.
63. Yasuda, S., Kachi, S., Kondo, M., Ushida, H., Uetani, R., Terui, T., et al. (2011). Significant correlation between electroretinogram parameters and ocular vascular endothelial growth factor concentration in central retinal vein occlusion eyes. Investigative Ophthalmology & Visual Science, 52(8), 5737-5742. doi:10.1167/iovs.10-6923.
64. Ferrara, N. (2010). Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nature Medicine, 16(10), 1107-1111. doi:10.1038/nm1010-1107.
65. Canavese, M., Altruda, F., Ruzicka, T., & Schauber, J. (2010). Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis - a possible target for novel therapies? Journal of Dermatological Science, 58(3), 171-176. doi:10.1016/j.jdermsci.2010.03.023.
66. Kurosaka, D., Hirai, K., Nishioka, M., Miyamoto, Y., Yoshida, K., Noda, K., et al. (2010). Clinical significance of serum levels of vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in patients with rheumatoid arthritis. Journal of Rheumatology, 37(6), 1121-1128. doi:10.3899/jrheum.090941.
67. Murata, M., Yudoh, K., & Masuko, K. (2008). The potential role of vascular endothelial growth factor (VEGF) in cartilage: how the angiogenic factor could be involved in the pathogenesis of osteoarthritis? Osteoarthritis and Cartilage, 16(3), 279-286. doi:10.1016/j.joca.2007.09.003. (Pubitemid 351309189)
68. Otto, K., Duchrow, M., Broll, R., Bruch, H. P., & Strik, M. W. (2002). Expression of vascular endothelial growth factor mRNA and protein in human chronic renal allograft rejection. Transplantation Proceedings, 34(8), 3134-3137. (Pubitemid 35463273)
69. Reinders, M. E., Fang, J. C.,Wong,W., Ganz, P., & Briscoe, D.M. (2003). Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation, 76(1), 224-230. doi:10.1097/01.tp.0000071363.55007.d0. (Pubitemid 36877141)
70. Nag, S., Kapadia, A., & Stewart, D. J. (2011). Review: molecular pathogenesis of blood-brain barrier breakdown in acute brain injury. Neuropathology and Applied Neurobiology, 37(1), 3-23. doi:10.1111/j.1365-2990. 2010.01138.x.
71. Przewratil, P., Sitkiewicz, A., & Andrzejewska, E. (2010). Local serum levels of vascular endothelial growth factor in infantile hemangioma: intriguing mechanism of endothelial growth. Cytokine, 49(2), 141-147. doi:10.1016/j.cyto.2009.11.012.
72. Celletti, F. L., Waugh, J. M., Amabile, P. G., Brendolan, A., Hilfiker, P. R., & Dake, M. D. (2001). Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Medicine, 7(4), 425-429. doi:10.1038/86490. (Pubitemid 32298544)
73. Nordlie, M. A., Wold, L. E., Simkhovich, B. Z., Sesti, C., &Kloner, R. A. (2006). Molecular aspects of ischemic heart disease: ischemia/reperfusion- induced genetic changes and potential applications of gene and RNA interference therapy. Journal of Cardiovascular Pharmacology and Therapeutics, 11 (1), 17-30.
74. Stehr, A., Topel, I., Muller, S., Unverdorben, K., Geissler, E. K., Kasprzak, P. M., et al. (2010). VEGF: a surrogate marker for peripheral vascular disease. European Journal of Vascular and Endovascular Surgery, 39(3), 330-332. doi:10.1016/j.ejvs.2009.09.025.
75. Chi, O. Z., Hunter, C., Liu, X., & Weiss, H. R. (2007). Effects of anti-VEGF antibody on blood-brain barrier disruption in focal cerebral ischemia. Experimental Neurology, 204(1), 283-287. doi:10.1016/j.expneurol.2006.11.001. (Pubitemid 46330278)
76. Peitsidis, P., & Agrawal, R. (2010). Role of vascular endothelial growth factor in women with PCO and PCOS: a systematicreview. Reproductive Biomedicine Online, 20(4), 444-452. doi:10.1016/j.rbmo.2010.01.007.
77. Ren, Q. Z., Qian, Z. H., Jia, S. H., & Xu, Z. Z. (2011). Vascular endothelial growth factor expression up-regulated by endometrial ischemia in secretory phase plays an important role in endometriosis. Fertility and Sterility, 95(8), 2687-2689. doi:10.1016/j.fertnstert.2011.05.001.
78. Murakami, Y., Kobayashi, T., Omatsu, K., Suzuki, M., Ohashi, R., Matsuura, T., et al. (2005). Exogenous vascular endothelial growth factor can induce preeclampsia-like symptoms in pregnant mice. Seminars in Thrombosis and Hemostasis, 31(3), 307-313. doi:10.1055/s-2005-872437. (Pubitemid 40962392)
79. Bussen, S., & Bussen, D. (2011). Influence of the vascular endothelial growth factor on the development of severe preeclampsia or HELLP syndrome. Archives of Gynecology and Obstetrics, 284(3), 551-557. doi:10.1007/s00404-010-1704-x.
80. Carmeliet, P. (2005). Angiogenesis in life, disease and medicine. Nature, 438(7070), 932-936. doi:10.1038/nature04478.
81. Volm, M., Koomagi, R., Mattern, J., & Stammler, G. (1997). Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. Anticancer Research, 17(1A), 99-103. (Pubitemid 27116651)
82. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Guidi, A. J., Dvorak, H. F., et al. (1995). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Human Pathology, 26(1), 86-91.
83. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Senger, D. R., et al. (1993). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Research, 53(19), 4727-4735. (Pubitemid 23304407)
84. Brown, L. F., Berse, B., Jackman, R. W., Tognazzi, K., Manseau, E. J., Dvorak, H. F., et al. (1993). Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. American Journal of Pathology, 143(5), 1255-1262. (Pubitemid 24057094)
85. Guidi, A. J., Abu-Jawdeh, G., Tognazzi, K., Dvorak, H. F., &Brown, L. F. (1996). Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer, 78(3), 454-460. doi:10.1002/(sici)1097-0142 (19960801)78:3〈454::aid-cncr12〉3. 0.co;2-y.
86. Huang, H., Held-Feindt, J., Buhl, R., Mehdorn, H. M., &Mentlein, R. (2005). Expression of VEGF and its receptors in different brain tumors. Neurological Research, 27(4), 371-377. doi:10.1179/016164105x39833. (Pubitemid 40734696)
87. Turner, H. E., Harris, A. L., Melmed, S., & Wass, J. A. (2003). Angiogenesis in endocrine tumors. Endocrine Reviews, 24(5), 600-632. (Pubitemid 37330584)
88. Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E. C., Lu, N., et al. (1998). Tumor induction of VEGF promoter activity in stromal cells. Cell, 94(6), 715-725. (Pubitemid 28436004)
89. Gerber, H. P., Kowalski, J., Sherman, D., Eberhard, D. A., &Ferrara, N. (2000). Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Research, 60(22), 6253-6258.
90. Folkman, J. (1971). Tumor angiogenesis: therapeutic implications. The New England Journal of Medicine, 285(21), 1182-1186. doi:10.1056/ nejm197111182852108.
91. Carmeliet, P. (2005). VEGF as a key mediator of angiogenesis in cancer. Oncology, 69(Suppl 3), 4-10. doi:10.1159/000088478.
92. Kamba, T., Tam, B. Y., Hashizume, H., Haskell, A., Sennino, B., Mancuso, M. R., et al. (2006). VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. American Journal of Physiology - Heart and Circulatory Physiology, 290(2), H560-H576. doi:10.1152/ajpheart.00133.2005.
93. Nor, J. E., Christensen, J., Liu, J., Peters, M., Mooney, D. J., Strieter, R. M., et al. (2001). Up-regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Research, 61(5), 2183-2188. (Pubitemid 32692045)
94. Folkman, J. (2003). Angiogenesis and apoptosis. Seminars in Cancer Biology, 13(2), 159-167.
95. Dvorak, H. F., Brown, L. F., Detmar, M., & Dvorak, A. M. (1995). Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology, 146(5), 1029-1039.
96. Unemori, E. N., Ferrara, N., Bauer, E. A., & Amento, E. P. (1992). Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. Journal of Cellular Physiology, 153(3), 557-562. doi:10.1002/jcp.1041530317.
97. Bamberger, E. S., & Perrett, C. W. (2002). Angiogenesis in epithelian ovarian cancer. Molecular Pathology, 55(6), 348-359. (Pubitemid 35454510)
98. Lichtenberger, B. M., Tan, P. K., Niederleithner, H., Ferrara, N., Petzelbauer, P., & Sibilia, M. (2010). Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell, 140(2), 268-279. doi:10.1016/j.cell.2009.12.046.
99. Mercurio, A. M., Bachelder, R. E., Bates, R. C., & Chung, J. (2004). Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin. Seminars in Cancer Biology, 14(2), 115-122. doi:10.1016/j.semcancer.2003.09.016. (Pubitemid 38234753)
100. Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., et al. (1996). Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Medicine, 2(10), 1096-1103. (Pubitemid 26338628)
101. Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., et al. (1998). Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. Journal of Immunology, 160(3), 1224-1232. (Pubitemid 28093419)
102. Kaplan, R. N., Riba, R. D., Zacharoulis, S., Bramley, A. H., Vincent, L., Costa, C., et al. (2005). VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature, 438(7069), 820-827. doi:10.1038/nature04186. (Pubitemid 41753060)
103. Gerber, H. P., & Ferrara, N. (2003). The role of VEGF in normal and neoplastic hematopoiesis. Journal Molecule Medicine (Berl), 81(1), 20-31. doi:10.1007/s00109-002-0397-4.
104. Medinger, M., Fischer, N., & Tzankov, A. (2010). Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies. Journal Oncology, 2010, 729725. doi:10.1155/2010/729725.
105. Olson, T. A., Mohanraj, D., Carson, L. F., & Ramakrishnan, S. (1994). Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Research, 54(1), 276-280. (Pubitemid 24042123)
106. Abu-Jawdeh, G. M., Faix, J. D., Niloff, J., Tognazzi, K., Manseau, E., Dvorak, H. F., et al. (1996). Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Laboratory Investigation, 74(6), 1105-1115. (Pubitemid 26184421)
107. Hazelton, D., Nicosia, R. F., & Nicosia, S. V. (1999). Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clinical Cancer Research, 5(4), 823-829. (Pubitemid 29180834)
108. Schumacher, J. J., Dings, R. P., Cosin, J., Subramanian, I. V., Auersperg, N., & Ramakrishnan, S. (2007). Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Research, 67(8), 3683-3690. doi:10.1158/0008-5472.can-06-3608. (Pubitemid 46762153)
109. Santin, A. D., Hermonat, P. L., Ravaggi, A., Cannon, M. J., Pecorelli, S., & Parham, G. P. (1999). Secretion of vascularendothelial growth factor in ovarian cancer. European Journal of Gynaecological Oncology, 20(3), 177-181. (Pubitemid 29286483)
110. Paley, P. J., Staskus, K. A., Gebhard, K., Mohanraj, D., Twiggs, L. B., Carson, L. F., et al. (1997). Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer, 80 (1), 98-106. (Pubitemid 27270925)
111. Kassim, S. K., El-Salahy, E. M., Fayed, S. T., Helal, S. A., Helal, T., Azzam Eel, D., et al. (2004). Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients. Clinical Biochemistry, 37(5), 363-369. doi:10.1016/j.clinbiochem.2004. 01.014. (Pubitemid 38490454)
112. Chambers, S. K., Clouser, M. C., Baker, A. F., Roe, D. J., Cui, H., Brewer, M. A., et al. (2010). Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clinical Cancer Research, 16(21), 5320-5328. doi:10.1158/1078-0432.ccr-10-0974.
113. Siddiqui, G. K., Elmasry, K., Wong Te Fong, A. C., Perrett, C., Morris, R., Crow, J. C., et al. (2010). Prognostic significance of intratumoral vascular endothelial growth factor as a marker of tumour angiogenesis in epithelial ovarian cancer. European Journal of Gynaecological Oncology, 31(2), 156-159.
114. Siddiqui, G. K.,Wong Te Fong, L. F., Rolfe, K. J., Hadjat, S., Reid, W. M. N., Maclean, A. B., et al. (2001). Abstracts presented at the Scientific Meeting, Portsmouth, 10th and 11th November 2000. BJOG: An International Journal of Obstetrics and Gynaecology, 108(5), 547-557. doi:10.1111/j.1471-0528.2001. 00126.x.
115. Zebrowski, B. K., Liu, W., Ramirez, K., Akagi, Y., Mills, G. B., & Ellis, L. M. (1999). Markedly elevated levels of vascular endothelial growth factor in malignant ascites. Annals of Surgical Oncology, 6(4), 373-378. (Pubitemid 29260800)
116. Bamias, A., Koutsoukou, V., Terpos, E., Tsiatas, M. L., Liakos, C., Tsitsilonis, O., et al. (2008). Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. Gynecologic Oncology, 108(2), 421-427. doi:10.1016/j.ygyno.2007.10.018.
117. Cooper, B. C., Ritchie, J. M., Broghammer, C. L., Coffin, J., Sorosky, J. I., Buller, R. E., et al. (2002). Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clinical Cancer Research, 8(10), 3193-3197. (Pubitemid 35155030)
118. Li, L., Wang, L., Zhang, W., Tang, B., Zhang, J., Song, H., et al. (2004). Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastasis and patient survival in ovarian cancer. Anticancer Research, 24(3b), 1973-1979. (Pubitemid 38954620)
119. Hefler, L. A., Zeillinger, R., Grimm, C., Sood, A. K., Cheng, W. F., Gadducci, A., et al. (2006). Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecologic Oncology, 103(2), 512-517. doi:10.1016/j.ygyno.2006.03.058. (Pubitemid 44740099)
120. Ferrara, N., & Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. Nature, 438(7070), 967-974. doi:10.1038/nature04483. (Pubitemid 43093963)
121. Osada, R., Horiuchi, A., Kikuchi, N., Ohira, S., Ota, M., Katsuyama, Y., et al. (2006). Expression of semaphorins, vascular endothelial growth factor, and their common receptor neuropilins and alleic loss of semaphorin locus in epithelial ovarian neoplasms: increased ratio of vascular endothelial growth factor to semaphorin is a poor prognostic factor in ovarian carcinomas. Human Pathology, 37(11), 1414-1425. doi:10.1016/j.humpath.2006.04.031. (Pubitemid 44584330)
122. Hefler, L. A., Mustea, A., Konsgen, D., Concin, N., Tanner, B., Strick, R., et al. (2007). Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clinical Cancer Research, 13(3), 898-901. doi:10.1158/1078-0432.ccr-06-1008. (Pubitemid 46340365)
123. Horiuchi, A., Imai, T., Shimizu, M., Oka, K., Wang, C., Nikaido, T., et al. (2002). Hypoxia-induced changes in the expression of VEGF, HIF-1 alpha and cell cycle-related molecules in ovarian cancer cells. Anticancer Research, 22(5), 2697-2702. (Pubitemid 36069300)
124. Skinner, H. D., Zheng, J. Z., Fang, J., Agani, F., & Jiang, B.-H. (2004). Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1α, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. Journal of Biological Chemistry, 279(44), 45643-45651. doi:10.1074/jbc.M404097200. (Pubitemid 39491552)
125. Kryczek, I., Lange, A., Mottram, P., Alvarez, X., Cheng, P., Hogan, M., et al. (2005). CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Research, 65(2), 465-472.
126. Cao, Z., Fang, J., Xia, C., Shi, X., & Jiang, B.-H. (2004). trans-3,4,5′-Trihydroxystibene inhibits hypoxia-inducible factor 1αand vascular endothelial growth factor expression in human ovarian cancer cells. Clinical Cancer Research, 10(15), 5253-5263. doi:10.1158/1078- 0432.ccr-03-0588. (Pubitemid 39099800)
127. Liu, L.-Z., Hu, X.-W., Xia, C., He, J., Zhou, Q., Shi, X., et al. (2006). Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1α expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radical Biology & Medicine, 41 (10), 1521-1533. doi:10.1016/j.freeradbiomed. 2006.08.003. (Pubitemid 44528250)
128. Matei, D., Kelich, S., Cao, L., Menning, N., Emerson, R. E., Rao, J., et al. (2007). PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biology & Therapy, 6(12), 1951-1959. (Pubitemid 351590409)
129. Liao, S., Liu, J., Lin, P., Shi, T., Jain, R. K., & Xu, L. (2011). TGF-beta blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models. Clinical Cancer Research, 17(6), 1415-1424. doi:10.1158/1078-0432.ccr-10-2429.
130. Kulbe, H., Thompson, R., Wilson, J. L., Robinson, S., Hagemann, T., Fatah, R., et al. (2007). The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Research, 67(2), 585-592. doi:10.1158/0008-5472.can-06-2941. (Pubitemid 46192196)
131. Dai, L., Gu, L., Ding, C., Qiu, L., & Di, W. (2009). TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression. Cancer Letters, 283(2), 159-167. doi:10.1016/j.canlet.2009.03.036.
132. Stadlmann, S., Amberger, A., Pollheimer, J., Gastl, G., Offner, F. A., Margreiter, R., et al. (2005). Ovarian carcinoma cells and IL-1beta-activated human peritoneal mesothelial cells are possible sources of vascular endothelial growth factor in inflammatory and malignant peritoneal effusions. Gynecologic Oncology, 97 (3), 784-789. doi:10.1016/j.ygyno.2005.02.017. (Pubitemid 40824647)
133. Coward, J., Kulbe, H., Chakravarty, P., Leader, D. A., Vassileva, V., Leinster, D. A., et al. (2011). Interleukin-6 as a therapeutic target in human ovarian cancer. Clinical Cancer Research. doi:10.1158/1078-0432.ccr-11-0945.
134. Salani, D., Di Castro, V., Nicotra, M. R., Rosano, L., Tecce, R., Venuti, A., et al. (2000). Role of endothelin-1 in neovascularization of ovarian carcinoma. American Journal of Pathology, 157 (5), 1537-1547. doi:10.1016/s0002-9440(10)64791-8.
135. Kandalaft, L. E., Motz, G. T., Duraiswamy, J., & Coukos, G. (2011). Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer and Metastasis Reviews, 30(1), 141-151.
136. Yokoyama, Y., Xin, B., Shigeto, T., & Mizunuma, H. (2011). Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition ofgrowth of human ovarian cancers. Journal of Cancer Research and Clinical Oncology, 137(8), 1219-1228. doi:10.1007/s00432-011-0993-1.
137. Schiffenbauer, Y. S., Abramovitch, R., Meir, G., Nevo, N., Holzinger, M., Itin, A., et al. (1997). Loss of ovarian function promotes angiogenesis in human ovarian carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 94(24), 13203-13208. (Pubitemid 27518500)
138. Wang, J., Luo, F., Lu, J. J., Chen, P. K., Liu, P., & Zheng, W. (2002). VEGF expression and enhanced production by gonadotropins in ovarian epithelial tumors. International Journal of Cancer, 97(2), 163-167. (Pubitemid 34019950)
139. Gao, N., Nester, R. A., & Sarkar, M. A. (2004). 4-Hydroxy estradiol but not 2-hydroxy estradiol induces expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor A through phosphatidylinositol 3-kinase/Akt/FRAP pathway in OVCAR-3 and A2780-CP70 human ovarian carcinoma cells. Toxicology and Applied Pharmacology, 196(1), 124-135. doi:10.1016/j.taap.2003.12.002. (Pubitemid 38393700)
140. Belotti, D., Paganoni, P., Manenti, L., Garofalo, A., Marchini, S., Taraboletti, G., et al. (2003). Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Research, 63(17), 5224-5229. (Pubitemid 37139832)
141. Xia, C., Meng, Q., Liu, L. Z., Rojanasakul, Y., Wang, X. R., &Jiang, B. H. (2007). Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Research, 67(22), 10823-10830. doi:10.1158/0008-5472.can-07-0783. (Pubitemid 350145911)
142. Gupta, R. A., Tejada, L. V., Tong, B. J., Das, S. K., Morrow, J. D., Dey, S. K., et al. (2003). Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Research, 63(5), 906-911. (Pubitemid 36278417)
143. Xin, B., Yokoyama, Y., Shigeto, T., Futagami, M., & Mizunuma, H. (2007). Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers. Cancer, 110(4), 791-800. doi:10.1002/cncr.22854. (Pubitemid 47257656)
144. Hu, Y. L., Tee, M. K., Goetzl, E. J., Auersperg, N., Mills, G. B., Ferrara, N., et al. (2001). Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. Journal of the National Cancer Institute, 93(10), 762-768. (Pubitemid 32514799)
145. Dutta, S., Wang, F. Q., Wu, H. S., Mukherjee, T. J., & Fishman, D. A. (2011). The NF-kappaB pathway mediates lysophosphatidic acid (LPA)-induced VEGF signaling and cell invasion in epithelial ovarian cancer (EOC). Gynecologic Oncology. doi:10.1016/j.ygyno.2011.06.006.
146. Zhang, L., Yang, N., Katsaros, D., Huang, W., Park, J. W., Fracchioli, S., et al. (2003). The oncogene phosphatidylinositol 3′-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Research, 63(14), 4225-4231. (Pubitemid 36917950)
147. Yang, G., Cai,K. Q., Thompson-Lanza, J.A., Bast, R. C., Jr., & Liu, J. (2004). Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. Journal of Biological Chemistry, 279(6), 4339-4345. doi:10.1074/jbc.M311153200. (Pubitemid 38199022)
148. Hennessy, B. T., Coleman, R. L., & Markman, M. (2009). Ovarian cancer. The Lancet, 374(9698), 1371-1382.
149. Mesiano, S., Ferrara, N., & Jaffe, R. B. (1998). Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. American Journal of Pathology, 153(4), 1249-1256. doi:10.1016/s0002-9440(10)65669-6. (Pubitemid 28465848)
150. Zhang, L., Yang, N., Park, J. W., Katsaros, D., Fracchioli, S., Cao, G., et al. (2003). Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Research, 63(12), 3403-3412. (Pubitemid 36735901)
151. Xia, C., Meng, Q., Cao, Z., Shi, X., & Jiang, B. H. (2006). Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression. Journal of Cellular Physiology, 209(1), 56-66. doi:10.1002/jcp. 20707. (Pubitemid 44318667)
152. Liby, T. A., Spyropoulos, P., Buff Lindner, H., Eldridge, J., Beeson, C., Hsu, T., et al. (2011). Akt3 controls vascular endothelial growth factor secretion and angiogenesis in ovarian cancer cells. International Journal of Cancer. doi:10.1002/ijc.26010.
153. Boocock, C. A., Charnock-Jones, D. S., Sharkey, A. M., McLaren, J., Barker, P. J., Wright, K. A., et al. (1995). Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. Journal of the National Cancer Institute, 87(7), 506-516.
154. Mattern, J., Stammler, G., Koomagi, R.,Wallwiener, D., Kaufmann, M., & Volm,M. (1997). Association of vascular endothelial growth factor expressionwith tumor cell proliferation in ovarian carcinoma. Anticancer Research, 17(1B), 621-624. (Pubitemid 27105537)
155. Chen, H., Ye, D., Xie, X., Chen, B., & Lu, W. (2004). VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecologic Oncology, 94(3), 630-635. doi:10.1016/j.ygyno.2004.05.056. (Pubitemid 39194453)
156. Spannuth, W. A., Nick, A. M., Jennings, N. B., Armaiz-Pena, G. N., Mangala, L. S., Danes, C. G., et al. (2009). Functional significance of VEGFR-2 on ovarian cancer cells. International Journal of Cancer, 124(5), 1045-1053. doi:10.1002/ijc.24028.
157. Sher, I., Adham, S. A., Petrik, J., & Coomber, B. L. (2009). Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. International Journal of Cancer, 124 (3), 553-561. doi:10.1002/ijc. 23963.
158. Trinh, X. B., Tjalma, W. A., Vermeulen, P. B., Van den Eynden, G., Van der Auwera, I., Van Laere, S. J., et al. (2009). The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. British Journal of Cancer, 100 (6), 971-978. doi:10.1038/sj.bjc.6604921.
159. Kaplan, R. N., Rafii, S., & Lyden, D. (2006). Preparing the "soil": the premetastatic niche. Cancer Research, 66(23), 11089-11093. doi:10.1158/0008-5472.can-06-2407.
160. Sawano, A., Iwai, S., Sakurai, Y., Ito, M., Shitara, K., Nakahata, T., et al. (2001). Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans. Blood, 97(3), 785-791. (Pubitemid 32113414)
161. Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., et al. (2000). Openings between defective endothelial cells explain tumor vessel leakiness. American Journal of Pathology, 156(4), 1363-1380. doi:10.1016/s0002-9440(10)65006-7. (Pubitemid 30660013)
162. Summy, J. M., & Gallick, G. E. (2003). Src family kinases in tumor progression and metastasis. Cancer and Metastasis Reviews, 22(4), 337-358. (Pubitemid 36791891)
163. Weis, S., Cui, J., Barnes, L., & Cheresh, D. (2004). Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. The Journal of Cell Biology, 167(2), 223-229. doi:10.1083/jcb.200408130. (Pubitemid 39435066)
164. Olson, T., Mohanraj, D., & Ramakrishnan, S. (1996). In vivo neutralization of vascular endothelial growth factor (VEGF) vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth. International Journal of Oncology, 8(3), 505-511.
165. Zhang, L., Yang, N., Garcia, J. R., Mohamed, A., Benencia, F., Rubin, S. C., et al. (2002). Generation of a syngeneic mousemodel to study the effects of vascular endothelial growth factor in ovarian carcinoma. American Journal of Pathology, 161(6), 2295-2309. (Pubitemid 35434873)
166. So, J., Wang, F. Q., Navari, J., Schreher, J., & Fishman, D. A. (2005). LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecologic Oncology, 97(3), 870-878. doi:10.1016/j.ygyno.2005.03.004. (Pubitemid 40824659)
167. Wang, F. Q., So, J., Reierstad, S., & Fishman, D. A. (2006). Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. International Journal of Cancer, 118 (4), 879-888. doi:10.1002/ijc.21421. (Pubitemid 43157663)
168. Zhang, A., Meng, L., Wang, Q., Xi, L., Chen, G., Wang, S., et al. (2006). Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2. Oncology Reports, 15(4), 831-836.
169. Belotti, D., Calcagno, C., Garofalo, A., Caronia, D., Riccardi, E., Giavazzi, R., et al. (2008). Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Molecular Cancer Research, 6 (4), 525-534. doi:10.1158/1541-7786.mcr- 07-0366. (Pubitemid 351521834)
170. Wang, J. Y., Sun, T., Zhao, X. L., Zhang, S. W., Zhang, D. F., Gu, Q., et al. (2008). Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry. Cancer Biology & Therapy, 7(5), 758-766.
171. Naora, H., & Montell, D. J. (2005). Ovarian cancer metastasis: integrating insights from disparate model organisms. Nature Reviews Cancer, 5(5), 355-366. doi:10.1038/nrc1611. (Pubitemid 40637827)
172. Ziogas, A. C., Gavalas, N. G., Tsiatas, M., Tsitsilonis, O., Politi, E., Terpos, E., et al. (2011). VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. International Journal of Cancer. doi:10.1002/ijc.26094.
173. Ahmed, N., Thompson, E. W., & Quinn, M. A. (2007). Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. Journal of Cellular Physiology, 213(3), 581-588. doi:10.1002/jcp.21240. (Pubitemid 350058249)
174. Shield, K., Ackland, M. L., Ahmed, N., & Rice, G. E. (2009). Multicellular spheroids in ovarian cancer metastases: biology and pathology. Gynecologic Oncology, 113(1), 143-148. doi:10.1016/j.ygyno.2008.11.032.
175. Carmignani, C. P., Sugarbaker, T. A., Bromley, C. M., &Sugarbaker, P. H. (2003). Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer and Metastasis Reviews, 22(4), 465-472. (Pubitemid 36791900)
176. Huynh, H., Teo, C. C. M., & Soo, K. C. (2007). Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer. Molecular Cancer Therapeutics, 6(11), 2959-2966. doi:10.1158/1535-7163.mct-07- 0237. (Pubitemid 350206774)
177. Fagotti, A., Gallotta, V., Romano, F., Fanfani, F., Rossitto, C., Naldini, A., et al. (2010). Peritoneal carcinosis of ovarian origin. World Journal Gastrointestinal Oncology, 2(2), 102-108. doi:10.4251/wjgo.v2.i2.102.
178. Chereau, E., Ballester, M., Selle, F., Cortez, A., Darai, E., &Rouzier, R. (2010). Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. American Journal of Obstetrics and Gynecology, 202(2), 178 e171-178 e110. doi:10.1016/j.ajog.2009.10.856.
179. Parsons, S. L., Lang, M. W., & Steele, R. J. (1996). Malignant ascites: a 2-year review from a teaching hospital. European Journal of Surgical Oncology, 22(3), 237-239. (Pubitemid 26229671)
180. Mackey, J. R., & Venner, P. M. (1996). Malignant ascites: demographics, therapeutic efficacy and predictors of survival. The Canadian Journal of Oncology, 6(2), 474-480.
181. Wilailak, S., Linasmita, V., & Srivannaboon, S. (1999). Malignant ascites in female patients: a seven-year review. Journal of the Medical Association of Thailand, 82(1), 15-19.
182. Ayantunde, A., & Parsons, S. (2007). Pattern and prognostic factors in patients with malignant ascites: a retrospective study. Annals of Oncology, 18(5), 945-949. doi:10.1093/annonc/mdl499. (Pubitemid 47054094)
183. Hirabayashi, K., & Graham, J. (1970). Genesis of ascites in ovarian cancer. American Journal of Obstetrics and Gynecology, 106(4), 492-497.
184. Byrne, A. T., Ross, L., Holash, J., Nakanishi, M., Hu, L., Hofmann, J. I., et al. (2003). Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clinical Cancer Research, 9(15), 5721-5728. (Pubitemid 37499496)
185. Pourgholami, M. H., Yan Cai, Z., Lu, Y., Wang, L., & Morris, D. L. (2006). Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clinical Cancer Research, 12(6), 1928-1935. doi:10.1158/1078-0432.ccr-05-1181.
186. Senger, D. R., Perruzzi, C. A., Feder, J., & Dvorak, H. F. (1986). A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Research, 46(11), 5629-5632. (Pubitemid 17177959)
187. Yeo, K. T., Wang, H. H., Nagy, J. A., Sioussat, T. M., Ledbetter, S. R., Hoogewerf, A. J., et al. (1993). Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Research, 53 (12), 2912-2918. (Pubitemid 23180536)
188. Nagy, J. A., Masse, E. M., Herzberg, K. T., Meyers, M. S., Yeo, K. T., Yeo, T. K., et al. (1995). Pathogenesis of ascites tumor growth: vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation. Cancer Research, 55(2), 360-368.
189. Luo, J. C., Yamaguchi, S., Shinkai, A., Shitara, K., & Shibuya, M. (1998). Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Research, 58(12), 2652-2660. (Pubitemid 28275440)
190. Hampl, M., Tanaka, T., Albert, P. S., Lee, J., Ferrari, N., & Fine, H. A. (2001). Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites. Human Gene Therapy, 12 (14), 1713-1729. doi:10.1089/104303401750476221. (Pubitemid 32911638)
191. Xu, L., Yoneda, J., Herrera, C., Wood, J., Killion, J. J., & Fidler, I. J. (2000). Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. International Journal of Oncology, 16(3), 445-454.
192. Hasumi, Y., Mizukami, H., Urabe, M., Kohno, T., Takeuchi, K., Kume, A., et al. (2002). Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Research, 62(7), 2019-2023. (Pubitemid 34408446)
193. Dong, W. G., Sun, X. M., Yu, B. P., Luo, H. S., & Yu, J. P. (2003). Role of VEGF and CD44v6 in differentiating benign from malignant ascites. World Journal of Gastroenterology, 9(11), 2596-2600.
194. Yabushita, H., Shimazu, M., Noguchi, M., Kishida, T., Narumiya, H., & Sawaguchi, K. (2003). Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer. Oncology Reports, 10(1), 89-95.
195. Cormio, G., Rossi, C., Cazzolla, A., Resta, L., Loverro, G., Greco, P., et al. (2003). Distant metastases in ovarian carcinoma. International Journal of Gynecological Cancer, 13(2), 125-129. (Pubitemid 37055465)
196. Akahira, J. I., Yoshikawa, H., Shimizu, Y., Tsunematsu, R., Hirakawa, T., Kuramoto, H., et al. (2001). Prognostic factors of stage IVepithelial ovarian cancer: a multicenter retrospective study. Gynecologic Oncology, 81(3), 398-403. doi:10.1006/gyno.2001.6172. (Pubitemid 32494653)
197. Huang, K. J., & Sui, L. H. (2011). The relevance and role of vascular endothelial growth factor C, matrix metalloproteinase-2and E-cadherin in epithelial ovarian cancer. Medical Oncology. doi:10.1007/s12032-010-9817-4.
198. Ferrara, N., Hillan, K. J., & Novotny, W. (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochemical and Biophysical Research Communications, 333(2), 328-335. doi:10.1016/j.bbrc.2005.05.132. (Pubitemid 40848295)
199. Hu, L., Hofmann, J., Zaloudek, C., Ferrara, N., Hamilton, T., &Jaffe, R. B. (2002). Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. American Journal of Pathology, 161(5), 1917-1924. doi:10.1016/s0002-9440(10)64467-7. (Pubitemid 35265548)
200. Mabuchi, S., Terai, Y., Morishige, K., Tanabe-Kimura, A., Sasaki, H., Kanemura, M., et al. (2008). Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model. Clinical Cancer Research, 14(23), 7781-7789. doi:10.1158/1078-0432.ccr-08-0243.
201. Wulff, C., Wilson, H., Rudge, J. S., Wiegand, S. J., Lunn, S. F., & Fraser, H. M. (2001). Luteal angiogenesis: prevention and intervention by treatment with vascular endothelial growth factor trap(A40). Journal of Clinical Endocrinology and Metabolism, 86(7), 3377-3386. (Pubitemid 32673511)
202. Hu, L., Hofmann, J., Holash, J., Yancopoulos, G. D., Sood, A. K., &Jaffe, R. B. (2005). Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clinical Cancer Research, 11(19 Pt 1), 6966-6971. doi:10.1158/1078-0432.ccr-05-0910. (Pubitemid 41428755)
203. Krupitskaya, Y., & Wakelee, H. A. (2009). Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Current Opinion in Investigational Drugs, 10(6), 597-605.
204. Spratlin, J. L., Cohen, R. B., Eadens, M., Gore, L., Camidge, D. R., Diab, S., et al. (2010). Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. Journal of Clinical Oncology, 28 (5), 780-787. doi:10.1200/JCO.2009.23.7537.
205. Wedge, S. R., Kendrew, J., Hennequin, L. F., Valentine, P. J., Barry, S. T., Brave, S. R., et al. (2005). AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Research, 65 (10), 4389-4400. doi:10.1158/0008-5472. CAN-04-4409. (Pubitemid 40775678)
206. Hirte, H. W., Vidal, L., Fleming, G. F., Sugimoto, A. K., Morgan, R. J., Biagi, J. J., et al. (2008). A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. Journal Clinical Oncology (Meeting Abstracts), 26(15-suppl), 5521.
207. Matulonis, U. A., Berlin, S., Ivy, P., Tyburski, K., Krasner, C., Zarwan, C., et al. (2009). Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. Journal of Clinical Oncology, 27(33), 5601-5606. doi:10.1200/JCO.2009.23.2777.
208. Holtz, D. O., Krafty, R. T., Mohamed-Hadley, A., Zhang, L., Alagkiozidis, I., Leiby, B., et al. (2008). Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. Journal of Translational Medicine, 6, 2. doi:10.1186/1479-5876-6-2.
209. Bauerschlag, D. O., Schem, C., Tiwari, S., Egberts, J. H., Weigel, M. T., Kalthoff, H., et al. (2010). Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. Anticancer Research, 30(9), 3355-3360.
210. Rauh-Hain, J. A., & Penson, R. T. (2008). Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. International Journal of Gynecological Cancer, 18(5), 934-936. doi:10.1111/j.1525-1438.2007.01156.x.
211. Biagi, J. J., Oza, A. M., Grimshaw, R., Ellard, S. L., Lee, U., Sederias, J., et al. (2008). A phase II study of sunitinib (SU11248) in patients (pts) with recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma-NCIC CTG IND 185. ASCO Meeting Abstracts, 26(15-suppl), 5522.
212. Matsumura, N., Mandai, M., Okamoto, T., Yamaguchi, K., Yamamura, S., Oura, T., et al. (2010). Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. Cancer Science, 101(12), 2658-2663. doi:10.1111/j.1349-7006.2010.01736.x.
213. DeGrendele, H., Chu, E., & Marshall, J. (2003). Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors. Clinical Colorectal Cancer, 3(1), 16-18. (Pubitemid 37220783)
214. Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., et al. (2008). Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. Journal of Clinical Oncology, 26(22), 3709-3714. doi:10.1200/JCO.2007.10.8332.
215. Matei, D., Sill, M. W., Lankes, H. A., DeGeest, K., Bristow, R. E., Mutch, D., et al. (2010). Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial. Journal of Clinical Oncology, 29 (1), 69-75. doi:10.1200/JCO.2009.26.7856.
216. Schroder, W., Witteveen, E., Abadie, S., Campone, M., Viens, P., Jalava, T., et al. (2005). A phase IB, open label, safety and pharmacokinetic (PK) study of escalating doses of PTK787/ZK 222584 in combination with paclitaxel and carboplatin in patients (PTs) with stage IIC to IV epithelial ovarian cancer. ASCO Meeting Abstracts, 23(16-suppl), 5042.
217. Wedge, S. R., Ogilvie, D. J., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., et al. (2002). ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Research, 62(16), 4645-4655.
218. Annunziata, C. M., Walker, A. J., Minasian, L., Yu, M., Kotz, H., Wood, B. J., et al. (2010). Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clinical Cancer Research, 16(2), 664-672. doi:10.1158/1078-0432.CCR-09-2308.
219. Hilberg, F., Roth, G. J., Krssak,M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., et al. (2008). BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Research, 68(12), 4774-4782. doi:10.1158/0008-5472.CAN-07-6307.
220. Ledermann, J. A., Rustin, G. J., Hackshaw, A., Kaye, S. B., Jayson, G., Gabra, H., et al. (2009). A randomized phase II placebo-controlled trial using maintenance therapy to evaluate the vascular targeting agent BIBF 1120 following treatment of relapsed ovarian cancer (OC). ASCO Meeting Abstracts, 27(15S), 5501.
221. Thaker, P. H., Yazici, S., Nilsson, M. B., Yokoi, K., Tsan, R. Z., He, J., et al. (2005). Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors. Clinical Cancer Research, 11(13), 4923-4933. doi:10.1158/1078-0432.CCR-04-2060. (Pubitemid 41557213)
222. Kamat, A. A., Kim, T. J., Landen, C. N., Jr., Lu, C., Han, L. Y., Lin, Y. G., et al. (2007). Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Research, 67(1), 281-288. doi:10.1158/0008-5472.CAN-06-3282. (Pubitemid 46142786)
223. Merritt, W. M., Nick, A. M., Carroll, A. R., Lu, C., Matsuo, K., Dumble, M., et al. (2010). Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer. Molecular Cancer Therapeutics, 9(4), 985-995. doi:10.1158/1535-7163.mct-09-0967.
224. Friedlander, M., Hancock, K. C., Rischin, D., Messing, M. J., Stringer, C. A., Matthys, G. M., et al. (2010). A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecologic Oncology, 119(1), 32-37. doi:10.1016/j.ygyno.2010.05.033.
225. Polverino, A., Coxon, A., Starnes, C., Diaz, Z., DeMelfi, T., Wang, L., et al. (2006). AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Research, 66(17), 8715-8721. doi:10.1158/0008-5472.can-05- 4665. (Pubitemid 44449188)
226. Hirte, H. W. (2009). Novel developments in angiogenesis cancer therapy. Current Oncology, 16(3), 50-54.
227. Cook, K. M., & Figg, W. D. (2010). Angiogenesis inhibitors: current strategies and future prospects. CA: A Cancer Journal for Clinicians, 60(4), 222-243. doi:10.3322/caac.20075.
228. Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., et al. (2007). Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nature Biotechnology, 25(8), 911-920. doi:10.1038/nbt1323. (Pubitemid 47236916)
229. Gaur, P., Bose, D., Samuel, S., & Ellis, L. M. (2009). Targeting tumor angiogenesis. Seminars in Oncology, 36(2 Suppl 1), S12-S19. doi:10.1053/j.seminoncol.2009.02.002.
230. Paez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Vinals, F., et al. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 15(3), 220-231. doi:10.1016/j.ccr.2009.01.027.
231. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009). Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell, 15(3), 232-239. doi:10.1016/j.ccr.2009.01.021.
232. Ebos, J. M., & Kerbel, R. S. (2011). Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nature Reviews Clinical Oncology, 8(6), 316. doi:10.1038/nrclinonc.2011.74.
233. Ocana, A., Amir, E., Vera, F., Eisenhauer, E. A., & Tannock, I. F. (2011). Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. Journal of Clinical Oncology, 29(3), 254-256. doi:10.1200/jco.2010.32.0275.
234. Hayes, D. F. (2011). Bevacizumab treatment for solid tumors: boon or bust? Journal of the American Medical Association, 305 (5), 506-508. doi:10.1001/jama.2011.57.
235. Cohn, D. E., Kim, K. H., Resnick, K. E., O'Malley, D. M., &Straughn, J. M., Jr. (2011). At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. Journal of Clinical Oncology, 29(10), 1247-1251. doi:10.1200/jco.2010.32.1075.
236. Hensley, M. L. (2011). Big costs for little gain in ovarian cancer. Journal of Clinical Oncology, 29(10), 1230-1232. doi:10.1200/jco.2010.34.0489.
237. Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E., & Sorosky, J. I. (2007). Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology, 25(33), 5165-5171. doi:10.1200/JCO.2007.11.5345. (Pubitemid 350237599)
238. Cannistra, S. A., Matulonis, U. A., Penson, R. T., Hambleton, J., Dupont, J., Mackey, H., et al. (2007). Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. Journal of Clinical Oncology, 25 (33), 5180-5186. doi:10.1200/JCO.2007.12.0782. (Pubitemid 350232248)
239. Micha, J. P., Goldstein, B. H., Rettenmaier, M. A., Genesen, M., Graham, C., Bader, K., et al. (2007). A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer. International Journal of Gynecological Cancer, 17(4), 771-776. doi:10.1111/j.1525-1438.2007.00886.x. (Pubitemid 47063333)
240. Garcia, A. A., Hirte, H., Fleming, G., Yang, D., Tsao-Wei, D. D., Roman, L., et al. (2008). Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. Journal of Clinical Oncology, 26(1), 76-82. doi:10.1200/JCO.2007.12.1939.
241. Richardson, D. L., Backes, F. J., Seamon, L. G., Zanagnolo, V., O'Malley, D. M., Cohn, D. E., et al. (2008). Combination gemcitabine, platinum, and bevacizumab for the treatment of recurrent ovarian cancer. Gynecologic Oncology, 111(3), 461-466. doi:10.1016/j.ygyno.2008.08.011.
242. Penson, R. T., Dizon, D. S., Cannistra, S. A., Roche, M. R., Krasner, C. N., Berlin, S. T., et al. (2009). Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. Journal of Clinical Oncology, 28(1), 154-159. doi:10.1200/JCO.2009.22.7900.
243. Rose, P. G., Drake, R., Braly, P. S., Bell, M. C., Wenham, R. M., Hines, J. H., et al. (2009). Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. ASCO Meeting Abstracts, 27(15S), 5546.
244. Brown, J. V., 3rd, Micha, J. P., Rettenmaier, M. A., Abaid, L. N., Lopez, K. L., & Goldstein, B. H. (2010). A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. International Journal of Gynecological Cancer, 20(7), 1132-1136.
245. Tillmanns, T. D., Lowe, M. P., Schwartzberg, L. S., Walker, M. S., & Stepanski, E. J. (2010). A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. ASCO Meeting Abstracts, 28(15-suppl), 5009.
246. Burger, R. A., Brady, M. F., Bookman, M. A., Walker, J. L., Homesley, H. D., Fowler, J., et al. (2010). Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. ASCO Meeting Abstracts, 28(18-suppl). LBA1.
247. McGonigle, K. F., Muntz, H. G., Vuky, J., Paley, P. J., Veljovich, D. S., Greer, B. E., et al. (2011). Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study. Cancer, 117(16), 3731-3740. doi:10.1002/cncr.25967.
248. del Carmen, M. G., Micha, J. P., Small, L. A., Street, D. G., Londhe, A., & McGowan, T. (2011). Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancers: results of a phase II study. ASCO Meeting Abstracts, 29(15-suppl), 5061.
249. Horowitz, N. S., Penson, R. T., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., et al. (2011). Safety, efficacy, and biomarker exploration in a phase ii study of bevacizumab, oxaliplatin, and gemcitabine in recurrent Mullerian carcinoma. Clinical Ovarian Cancer Other Gynecology Malignant, 4(1), 26-33. doi:10.1016/j.cloc.2011.04.003.
250. Wenham, R., LaPolla, J., Hui-Yi, L., Apte, S., Roberts, W., Lancaster, J., et al. (2011). Phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. Gynecologic Oncology, 120 (Supplement 1(0)), S83-S84. doi:10.1016/j.ygyno.2010. 12.199.
251. Aghajanian, C., Finkler, N. J., Rutherford, T., Smith, D. A., Yi, J., Parmar, H., et al. (2011). OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy withor without bevacizumab (BEV) in patients with platinumsensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). ASCO Meeting Abstracts, 29(15-suppl), LBA5007.
252. Kristensen, G., Perren, T., Qian, W., Pfisterer, J., Ledermann, J. A., Joly, F., et al. (2011). Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. ASCO Meeting Abstracts, 29(15-suppl), LBA5006.
253. Kudoh, K., Takano, M., Kouta, H., Kikuchi, R., Kita, T., Miyamoto, M., et al. (2011). Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecologic Oncology, 122(2), 233-237. doi:10.1016/j.ygyno.2011.04.046.
254. O'Malley, D. M., Richardson, D. L., Rheaume, P. S., Salani, R., Eisenhauer, E. L., McCann, G. A., et al. (2011). Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer. Gynecologic Oncology, 121(2), 269-272. doi:10.1016/j.ygyno.2011.01.009.
255. Ojeda, B., Casado, A., Tibau, A., Redondo, A., Beltran, M., Garcia-Martinez, E., et al. (2011). Bevacizumab alone or with chemotherapy in highly pretreated, relapsed, epithelial ovarian cancer patients. ASCO Meeting Abstracts, 29(15-suppl), e15590.
256. Tew, W. P., Colombo, N., Ray-Coquard, I., Oza, A., del Campo, J., Scambia, G., et al. (2007). VEGF-trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. Journal Clinical Oncology (Meeting Abstracts), 25(18-suppl), 5508.
257. Colombo, N., Mangili, G., Mammoliti, S., Kalling, M., Tholander, B., Sternas, L., et al. (2008). Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: preliminary results of a pilot study. Journal Clinical Oncology (Meeting Abstracts), 26(15-suppl), 14598.
258. Coleman, R. L., Duska, L. R., Ramirez, P. T., Modesitt, S. C., Schmeler, K. M., Iyer, R., et al. (2011). Phase II multi-institutional study of docetaxel plus aflibercept (AVE0005, NSC# 724770) in patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer. ASCO Meeting Abstracts, 29(15-suppl), 5017.